Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
300.75
+1.24 (0.41%)
At close: Jun 27, 2025, 4:00 PM
296.00
-4.75 (-1.58%)
After-hours: Jun 27, 2025, 5:57 PM EDT
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $137.25M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $317.38M. In the year 2024, Madrigal Pharmaceuticals had annual revenue of $180.13M.
Revenue (ttm)
$317.38M
Revenue Growth
n/a
P/S Ratio
19.42
Revenue / Employee
$601,104
Employees
528
Market Cap
6.68B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MDGL News
- 8 days ago - Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval - Market Watch
- 8 days ago - Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis - GlobeNewsWire
- 10 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewsWire
- 6 weeks ago - In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals - Seeking Alpha
- 7 weeks ago - Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewsWire
- 7 weeks ago - Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra - Seeking Alpha
- 2 months ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript - Seeking Alpha